[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209 – 249. doi: 10.3322/caac.21660
|
[2] |
刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1 – 13.
|
[3] |
Schwartz AG, Cote ML. Epidemiology of lung cancer[J]. Advances in Experimental Medicine and Biology, 2016, 893: 21 – 41.
|
[4] |
Zhao LP. The tale of our other genome[J]. Nature, 2010, 465(7300): 879 – 880. doi: 10.1038/465879a
|
[5] |
Mao QX, Jiang F, Yin R, et al. Interplay between the lung microbiome and lung cancer[J]. Cancer Letters, 2018, 415: 40 – 48. doi: 10.1016/j.canlet.2017.11.036
|
[6] |
Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal[J]. Microbiome, 2015, 3: 31. doi: 10.1186/s40168-015-0094-5
|
[7] |
Lemon KP, Klepac-Ceraj V, Schiffer HK, et al. Comparative analyses of the bacterial microbiota of the human nostril and oropharynx[J]. mBio, 2010, 1(3): e00129 – 10.
|
[8] |
张鑫. 肺癌患者呼吸道菌群结构及代谢组特征分析与比较研究[D]. 上海: 中国人民解放军海军军医大学, 2019: 83 – 86.
|
[9] |
Dickson RP, Erb-Downward JR, Huffnagle GB. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis[J]. The Lancet Respiratory Medicine, 2014, 2(3): 238 – 246. doi: 10.1016/S2213-2600(14)70028-1
|
[10] |
Bassis CM, Erb-Downward JR, Dickson RP, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals[J]. mBio, 2015, 6(2): e00037.
|
[11] |
杨晓晖, 董航明, 蔡绍曦. 人体微生物组与肺癌[J]. 中国呼吸与危重监护杂志, 2017, 16(4): 417 – 420. doi: 10.7507/1671-6205.201701012
|
[12] |
Kovaleva O, Podlesnaya P, Rashidova M, et al. Lung microbiome differentially impacts survival of patients with non-small cell lung cancer depending on tumor stroma phenotype[J]. Biomedicines, 2020, 8(9): 349. doi: 10.3390/biomedicines8090349
|
[13] |
Dong H, Tan Q, Xu YY, et al. Convergent alteration of lung tissue microbiota and tumor cells in lung cancer[J]. iScience, 2022, 25(1): 103638. doi: 10.1016/j.isci.2021.103638
|
[14] |
Jang HJ, Choi JY, Kim K, et al. Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer[J]. Respiratory Research, 2021, 22(1): 322. doi: 10.1186/s12931-021-01919-1
|
[15] |
Liu HX, Tao LL, Zhang J, et al. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects[J]. International Journal of Cancer, 2018, 142(4): 769 – 778. doi: 10.1002/ijc.31098
|
[16] |
Huang DH, Su XF, Yuan M, et al. The characterization of lung microbiome in lung cancer patients with different clinico-pathology[J]. America Journal of Cancer Research, 2019, 9(9): 2047 – 2063.
|
[17] |
Meyer MS, Joshipura K, Giovannucci E, et al. A review of the relationship between tooth loss, periodontal disease, and cancer[J]. Cancer Causes and Control, 2008, 19(9): 895 – 907. doi: 10.1007/s10552-008-9163-4
|
[18] |
Bingula R, Filaire E, Molnar I, et al. Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial[J]. Respiratory Research, 2020, 21(1): 129. doi: 10.1186/s12931-020-01392-2
|
[19] |
Takiishi T, Fenero CIM, Câmara NOS. Intestinal barrier and gut microbiota: shaping our immune responses throughout life[J]. Tissue Barriers, 2017, 5(4): e1373208. doi: 10.1080/21688370.2017.1373208
|
[20] |
滕俊, 赵艳芬, 姜云宁, 等. 肠道菌群与肺癌的相关性[J]. 中国肺癌杂志, 2020, 23(10): 909 – 915. doi: 10.3779/j.issn.1009-3419.2020.101.39
|
[21] |
Zhang WQ, Zhao SK, Luo JW, et al. Alterations of fecal bacterial communities in patients with lung cancer[J]. America Journal of Translational Research, 2018, 10(10): 3171 – 3185.
|
[22] |
Bingula R, Filaire M, Radosevic-Robin N, et al. Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma[J]. Medicine, 2018, 97(50): e13676. doi: 10.1097/MD.0000000000013676
|
[23] |
Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis[J]. PLoS One, 2011, 6(3): e17479. doi: 10.1371/journal.pone.0017479
|
[24] |
Schreiber H, Nettesheim P, Lijinsky W, et al. Induction of lung cancer in germfree, specific-pathogen-free, and infected rats by N-nitrosoheptamethyleneimine: enhancement by respiratory infec-tion[J]. Journal of the National Cancer Institute, 1972, 49(4): 1107 – 1114.
|
[25] |
Qiao D, Wang ZY, Lu YH, et al. A retrospective study of risk and prognostic factors in relation to lower respiratory tract infection in elderly lung cancer patients[J]. America Journal of Cancer Research, 2015, 5(1): 423 – 432.
|
[26] |
章树佳. 慢性阻塞性肺病对肺癌患者肺部菌群构成影响的相关性研究[D]. 广州: 南方医科大学, 2020: 52 – 54.
|
[27] |
Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention[J]. COPD, 2008, 5(4): 235 – 256. doi: 10.1080/15412550802237531
|
[28] |
Jin CC, Lagoudas GK, Zhao C, et al. Commensal microbiota promote lung cancer development via γδ T cells[J]. Cell, 2019, 176(5): 998 – 1013.e16. doi: 10.1016/j.cell.2018.12.040
|
[29] |
Helmink BA, Khan MAW, Hermann A, et al. The microbiome, cancer, and cancer therapy[J]. Nature Medicine, 2019, 25(3): 377 – 388. doi: 10.1038/s41591-019-0377-7
|
[30] |
Cheng C, Wang ZF, Wang JQ, et al. Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer[J]. Translational Lung Cancer Research, 2020, 9(3): 693 – 704. doi: 10.21037/tlcr-19-590
|
[31] |
Yan XM, Yang MX, Liu J, et al. Discovery and validation of potential bacterial biomarkers for lung cancer[J]. America Journal of Cancer Research, 2015, 5(10): 3111 – 3122.
|
[32] |
Zheng YJ, Fang ZY, Xue Y, et al. Specific gut microbiome signature predicts the early-stage lung cancer[J]. Gut Microbes, 2020, 11(4): 1030 – 1042. doi: 10.1080/19490976.2020.1737487
|
[33] |
Ma Y, Qiu MT, Wang SD, et al. Distinct tumor bacterial microbiome in lung adenocarcinomas manifested as radiological subsolid nodules[J]. Translational Oncology, 2021, 14(6): 101050. doi: 10.1016/j.tranon.2021.101050
|
[34] |
Lee SH, Sung JY, Yong D, et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions[J]. Lung Cancer, 2016, 102: 89 – 95. doi: 10.1016/j.lungcan.2016.10.016
|
[35] |
Jin YP, Dong H, Xia LL, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC[J]. Journal of Thoracic Oncology, 2019, 14(8): 1378 – 1389. doi: 10.1016/j.jtho.2019.04.007
|
[36] |
Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371): 97 – 103. doi: 10.1126/science.aan4236
|
[37] |
He DQ, Li X, An R, et al. Response to PD-1-based immunotherapy for non-small cell lung cancer altered by gut microbiota[J]. Oncology and Therapy, 2021, 9(2): 647 – 657. doi: 10.1007/s40487-021-00171-3
|